Journal article icon

Journal article

Should we increase GFR with bardoxolone in Alport syndrome?

Abstract:

Bardoxolone methyl is a semisynthetic oleanane triterpenoid, and it is thought to act by promoting the resolution of inflammation via activation of Nrf-2 and inhibition of NF k–light-chain enhancer of activated B cells. Initial phase 1 studies showed, as an incidental finding, that bardoxolone increased eGFR, which generated interest in its potential as a drug to delay the progression of CKD. Subsequently, the 52-week Bardoxolone Methyl Treatment: Renal Function in CKD/Type 2 Diabetes (BEAM) ...

Expand abstract
Publication status:
Published
Peer review status:
Reviewed (Other)

Actions


Access Document


Publisher copy:
10.1681/ASN.2017101062

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Nuffield Department of Population Health; Clinical Trials Service Unit
Publisher:
American Society of Nephrology Publisher's website
Journal:
Journal of the American Society of Nephrology Journal website
Volume:
29
Issue:
2
Pages:
357-359
Publication date:
2018-01-05
Acceptance date:
2017-12-23
DOI:
EISSN:
1533-3450
ISSN:
1046-6673
Pubs id:
pubs:822220
URN:
uri:99c831f2-e3de-4f6e-b323-7d14def4e0a9
UUID:
uuid:99c831f2-e3de-4f6e-b323-7d14def4e0a9
Local pid:
pubs:822220

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP